When Should Open-Label Extension Studies Be Stopped?

被引：0
|
作者：
Crites, Joshua S. [1 ]
机构：
[1] Penn State Coll Med, Hershey, PA 17033 USA
来源：
AMERICAN JOURNAL OF BIOETHICS | 2014年 / 14卷 / 04期
关键词：
CLINICAL-TRIALS;
D O I：
10.1080/15265161.2014.889957
中图分类号：
B82 [伦理学（道德学）];
学科分类号：
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [41] INTERIM ANALYSIS OF NINTEDANIB IN AN OPEN-LABEL EXTENSION OF THE INPULSIS® TRIALS (INPULSIS®-ON)
    Crestani, Bruno
    Ogura, Takashi
    Pelling, Katy
    Coeck, Carl
    Quaresma, Manuel
    Kreuter, Michael
    Kaye, Mitchell
    RESPIROLOGY, 2015, 20 : 82 - 82
  • [42] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Samuel Frank
    Claudia Testa
    Mary C. Edmondson
    Jody Goldstein
    Elise Kayson
    Blair R. Leavitt
    David Oakes
    Christine O’Neill
    Christina Vaughan
    Jacquelyn Whaley
    Nicholas Gross
    Mark Forrest Gordon
    Juha-Matti Savola
    CNS Drugs, 2022, 36 : 1207 - 1216
  • [43] An Open-Label Extension Study of Alendronate Treatment in Elderly Women with Osteoporosis
    R. W. Downs, Jr.
    H. G. Bone
    H. McIlwain
    M. Z. Baker
    A. J. Yates
    A. Lombardi
    D. Krupa
    R. Harning
    Calcified Tissue International, 1999, 64 : 463 - 469
  • [44] Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
    Gleich, Gerald J.
    Roufosse, Florence
    Chupp, Geoffrey
    Faguer, Stanislas
    Walz, Bastian
    Reiter, Andreas
    Yancey, Steven W.
    Bentley, Jane H.
    Steinfeld, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (12): : 4431 - +
  • [45] Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
    Humbert, Marc
    McLaughlin, Vallerie
    Gibbs, J. Simon R.
    Gomberg-Maitland, Mardi
    Hoeper, Marius M.
    Preston, Ioana R.
    Souza, Rogerio
    Waxman, Aaron B.
    Ghofrani, Hossein-Ardeschir
    Subias, Pilar Escribano
    Feldman, Jeremy
    Meyer, Gisela
    Montani, David
    Olsson, Karen M.
    Manimaran, Solaiappan
    Pena, Janethe de Oliveira
    Badesch, David B.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (01)
  • [46] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Beyer, D.
    Iglesias-Rodriguez, M.
    Simon, A.
    Martincova, R.
    Burmester, G. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
  • [47] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Frank, Samuel
    Testa, Claudia
    Edmondson, Mary C.
    Goldstein, Jody
    Kayson, Elise
    Leavitt, Blair R.
    Oakes, David
    O'Neill, Christine
    Vaughan, Christina
    Whaley, Jacquelyn
    Gross, Nicholas
    Gordon, Mark Forrest
    Savola, Juha-Matti
    CNS DRUGS, 2022, 36 (11) : 1207 - 1216
  • [48] INTERIM ANALYSIS OF NINTEDANIB IN AN OPEN-LABEL EXTENSION OF THE INPULSIS® TRIALS (INPULSIS®-ON)
    Corte, T.
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Coeck, C.
    Quaresma, M.
    Kreuter, M.
    Kaye, M.
    RESPIROLOGY, 2016, 21 : 66 - 66
  • [49] Results of switching to laquinimod in the open-label extension phase of the BRAVO study
    Vollmer, T.
    Sorensen, P. S.
    Selmaj, K.
    Zipp, F.
    Havrdova, E.
    Cohen, J.
    Sidi, Y.
    Gorfine, T.
    Arnold, D.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 489 - 489
  • [50] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Simon, J-Abraham
    Martincova, Renata
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345